Abstract
Caveolin-1 plays an important role in the pathogenesis of multiple malignancies, and its expression also strongly affects the outcomes of patients with cancer. The objective of this study was to determine the clinical significance of the serum levels of caveolin-1 in patients with melanoma. A total of 60 patients with a pathologically confirmed diagnosis of melanoma were enrolled into this study. Serum caveolin-1 concentrations were determined by the solid-phase sandwich enzyme-linked immunosorbent assay method. Thirty age- and sex-matched healthy controls were included in the analysis. The median age at diagnosis was 53.5years, range 16-88years. The baseline serum caveolin-1 levels of the patients with melanoma were significantly higher than in those in the control group (0.47 vs. 0.37ng/ml, respectively, P=0.05). Known clinical variables, including age of patient, gender, site of lesion, histology, stage of disease, serum lactic dehydrogenase levels, and response to chemotherapy, were not found correlated with serum caveolin-1 concentrations (P>0.05). Moreover, serum caveolin-1 concentration was found to have no prognostic role on survival (P=0.44). Serum levels of caveolin-1 may have a diagnostic marker in melanoma patients. However, its predictive and prognostic value was not determined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
